JAK2 and essential thrombocythemia: While data on JAK2 mutation status were universally available, only a small subset of patients had data regarding the status of myeloproliferative leukemia virus oncogene (MPL) and calreticulin (CARL) mutations, which are estimated to occur in approximately 4% and 20% of ET patients.